Tag:
bluebird bio
Latest Headlines
Latest Headlines
UPDATED: PTC, Esperion, bluebird join the IPO frenzy in biotech with genetic therapies
Two more biotech outfits emerged this week as contenders to complete initial public offerings, highlighting the open season for the deals this year. Bluebird bio and PTC Therapeutics has mounted campaigns to go public with pipelines that target the molecular causes of rare genetic diseases.
UPDATED: Celgene makes big splash in gene therapy with two key cancer collaborations
Celgene has made a move into the resurgent gene therapy field. With a focus on immunotherapies against cancer, Celgene revealed collaborations with a pair of partners on Thursday that highlights increased industry interest in the previously shunned gene therapy field after a series of regulatory and scientific victories in recent years.
ViaCyte, Bluebird score $19.4M in CA stem cell funds for game-changing therapies
California has steered nearly $20 million in stem cell awards to a pair of biotech companies working on potentially revolutionary treatments for diabetes and the blood disorder beta-thalassemia.
Defining 'fierce' in the modern age of drug and device development
Now, more than ever, the life sciences industry is all about innovative and disruptive technologies. Every year for the past decade, FierceBiotech has made its picks on which companies hold the best odds for success in our Fierce 15 report . This year, though, we've added another Fierce 15 to focus on medical devices and diagnostics. I'd like to encourage readers to consider the differences by comparing the companies in each report.
FierceBiotech's 2012 Fierce 15 at BioPharm America
Nick Leschly, the CEO of Bluebird Bio, playfully dubbed the ambitious spirit of biotechs Levin Syndrome, a fictional affliction named after Third Rock Ventures' Mark Levin that compels biotech entrepreneurs to, as they say, go big or go home. Our Fierce 15 companies are all "going big." They also went home… with trophies. Check out the slideshow below.
The Fierce 15: An appetite for risk is healthy in drug development
There's more than one way to build a biotech company. And this year's Fierce 15 companies reflect a range of companies operating with a spectrum of business models. Here's the full report >>
Click here to view a video of FierceBiotech Editor John Carroll announcing the Fierce 15 at BioPharm America >>
Bluebird adds $60M venture haul to fuel pivotal gene therapy study
Bluebird bio is singing a sweet song today, to the tune of $60 million. That's the amount its lineup of investors--including the newly arrived Shire--is sinking into the Cambridge, MA-based biotech as it prepares a pivotal Phase II/III study for its lead gene therapy and brings along the next two programs in the pipeline.
Bluebird's gene therapy song attracts $30M venture round
Arch Venture Partners has joined a group of top venture players to help back Cambridge, MA-based bluebird bio with a $30 million venture commitment, capping a $35 million round completed a little
Bluebird bio's gene therapy plans hit a high note
Over the last week, Cambridge, MA-based bluebird bio has taken several key steps forward. The gene therapy pioneer named Alexandre LeBeaut as its new chief medical officer, signed up an impressive
Bluebird bio's gene therapy hits a high note
Over the last week, Cambridge, MA-based bluebird bio has taken several key steps forward. The gene therapy pioneer named Alexandre LeBeaut as its new chief medical officer, signed up an impressive
